Intelligence Platform

Patents

Browse 29,054 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 12049487

Universal chimeric antigen receptor T-cell preparation technique

GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12048692

Methods for treating chronic obstructive pulmonary disease

Theravance Biopharma R&D IP, LLC · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049510

Chimeric antigen receptor

AUTOLUS LIMITED · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049628

Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventin

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049630

Factor XII (F12) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049642

Corneal endothelial cells with increased cell density and compositions thereof

Astellas Institute for Regenerative Medicine · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049652

PH20 polypeptide variants, formulations and uses thereof

HALOZYME, INC. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049645

Differentiation of pancreatic endocrine cells

Vertex Pharmaceuticals Incorporated · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12048699

Cancer treatment methods based on TP53 mutation status and hypermutation

Takeda Pharmaceutical Company Limited · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049471

Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof

NURIX THERAPEUTICS, INC. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12043847

Compositions and methods for treating acne

The Regents of the University of California · Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12043833

Targeted compositions

ARBUTUS BIOPHARMA CORPORATION · Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12043843

Materials and methods for treatment of hemoglobinopathies

Vertex Pharmaceuticals Incorporated · Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12043667

CLEC12a binding polypeptides and uses thereof

Inhibrx Biosciences, Inc. · Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12043640

Prodrugs of STAT3 inhibitors

Tvardi Therapeutics, Inc. · Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12043660

10E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their u

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12042554

Compositions and methods for blocking ultraviolet radiation

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12043831

Modulation of alpha synuclein expression

Ionis Pharmaceuticals, Inc. · Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12043601

N-substituted-1H-1,2,4-triazole-3-carboxamides, analogues thereof, and methods of treatmen

The Regents of the University of Colorado · Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12043629

RIP1K inhibitors

Rigel Pharmaceuticals, Inc. · Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12042510

Modulators of IRF4 expression

Ionis Pharmaceuticals, Inc. · Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12042529

Optimization of enzyme replacement therapy for treatment of homocystinuria

The Regents of the University of Colorado, a Body Corporate · Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12042538

Methods of reducing particle formation and compositions formed thereby

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12042487

Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted